Nvidia carries the tape, and the Fed gets the last word

Nvidia reported better than expected fiscal second quarter results and, more importantly, guided next quarter's revenue above what Wall Street was looking for. The stock jumped roughly 7 to 9 percent, and that single move was enough to drag the Nasdaq up 1.32 percent while the rest of the market barely budged. That last part is the detail worth holding onto: technology was the only S&P 500 sector to finish higher on the day. A market where one sector carries the index is a narrow market, and narrow markets are more fragile than the headline number suggests, because the same handful of names that lifted it can just as easily take it back down. Salesforce, up more than 11 percent, and CrowdStrike, up 9 percent, added to the software strength. The guidance is the piece that actually mattered, because guidance is a statement about future demand rather than past results, and it told investors that AI orders are still accelerating rather than plateauing. That reads through directly to Amazon's GPU order and to TSMC's expansion, since they are three links in the same chain.

Every data center announcement you read this year assumes electricity will show up on schedule, and increasingly it does not. Transformer procurement has become a genuine constraint on data center development, with lead times stretching long enough that electrical equipment, not land or permits or chips, now decides when a site opens. Grid operators are under pressure to connect enormous new loads quickly, and regulators have started forcing timelines. The interesting part for an investor is who benefits: this is a windfall for extremely dull companies that make transformers, switchgear, and grid hardware, businesses that spent two decades with flat demand and no pricing power. When a boring supplier suddenly has a multi-year backlog and customers who cannot shop around, margins move in a way the market is often slow to price. It is also a real risk to the AI story, because if power equipment cannot be delivered, announced data center capacity slips regardless of how many GPUs were ordered. Worth tracking as the physical reality check on every AI headline in this brief.

This is the most direct policy-to-stock story on the board right now. Rare earth permanent magnets are the small, extremely strong magnets inside electric motors, wind turbines, missiles, drones, and fighter jets, and China makes almost all of them. At the Defense and Innovation Summit in July, President Trump told American industry plainly to fix that, saying "Magnets. Do magnets." What makes this different from a normal policy speech is that the government followed it with money and ownership. The Department of Defense took a roughly 15 percent equity stake in MP Materials through a $400 million investment, paired with a ten year supply agreement and a price floor for its Texas facility, which effectively guarantees the company a customer and a minimum price. It is also taking about a 10 percent stake in USA Rare Earth as part of a $1.6 billion package covering an Oklahoma magnet plant and Texas mining. In August the White House announced roughly $2 billion more across mining and critical minerals, including $150 million to Niron Magnetics for magnets that use no rare earths at all, $1.4 billion to Sila Nanotechnologies for battery anodes, and $400 million for scandium. The plain mechanic for an investor is that a price floor and a guaranteed buyer turn a speculative mining company into something closer to a utility, which is exactly why these names have run: USA Rare Earth is up about 44 percent year to date and MP Materials about 9 percent. The risk is that the same government support is what the valuations now depend on, so a change in administration priorities or a thaw with China on rare earth exports would cut both ways.

President Trump's most favored nation drug pricing push is the other policy with direct stock market plumbing. The idea is that Americans should not pay more for a medicine than people in other wealthy countries do, and the administration has been signing companies up one at a time rather than passing a law. Fourteen or more drugmakers have already agreed, including Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca, Merck, Amgen, Bristol Myers Squibb, Gilead, GSK, Novartis, and Sanofi, and the White House was reported this week to be preparing another round of deals with biotech companies. The trade each company makes is simple: offer discounts on a named list of drugs, and get three years of relief from pharmaceutical tariffs in return. Here is the part that matters for the stocks: analysts have generally judged the financial hit to be small, because the discounted drugs tend to be ones already heavily rebated or close to losing patent protection. Biopharma shares have actually risen on these announcements, which tells you the market reads them as removing tariff risk rather than cutting profits. The risk to watch is if a future round targets high-revenue drugs still under patent, because that is when the discounts would start biting real earnings. For now, treat each new signing as mildly positive for the company involved and a reminder that tariff relief is the actual currency being traded.

Jackson Hole is an annual gathering where the head of the Federal Reserve traditionally lays out how he is thinking about the economy, and markets treat it as the closest thing to a policy preview. Warsh took the job in May, and since then Treasury yields have moved up meaningfully, with the two year yield climbing to about 4.23 percent. A rising two year yield is the bond market's way of saying it expects interest rates to stay higher for longer. The pressure on Warsh today is inflation, because the latest reading came in above what economists expected, and he has not yet given a clear account of how hard he intends to fight it. If he sounds tough on inflation, the plain mechanic is that rate cut hopes get pushed further out, bond yields rise, and expensive growth and technology stocks usually fall the hardest because their value depends on profits far in the future. If he sounds relaxed and signals patience, you generally get the opposite: yields ease and stocks rally. Given how calm the VIX is, the market is not priced for the tough version. This is the one to watch today.